Research Analysts Set Expectations for BioLineRx Ltd.’s Q1 2024 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for BioLineRx in a research report issued on Tuesday, March 26th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.29) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for BioLineRx’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.24) EPS and Q4 2024 earnings at ($0.22) EPS.

Separately, StockNews.com upgraded shares of BioLineRx to a “sell” rating in a report on Wednesday.

BioLineRx Trading Up 0.9 %

Shares of BioLineRx stock opened at $1.12 on Thursday. The stock has a market capitalization of $81.13 million, a PE ratio of -1.24 and a beta of 1.40. BioLineRx has a 52 week low of $0.81 and a 52 week high of $2.53. The stock has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.46. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.86 and a current ratio of 1.96.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, March 26th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. The company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same period in the prior year, the company earned ($0.09) earnings per share.

Institutional Trading of BioLineRx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 189,678 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in shares of BioLineRx in the first quarter valued at $178,000. Envestnet Asset Management Inc. purchased a new position in shares of BioLineRx during the 1st quarter valued at $88,000. LPL Financial LLC increased its holdings in BioLineRx by 152.7% in the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 71,134 shares during the last quarter. Finally, PVG Asset Management Corp bought a new stake in BioLineRx in the 4th quarter valued at about $97,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.